» Articles » PMID: 34602013

Adipocytokines in Graves' Orbitopathy and the Effect of High-dose Corticosteroids

Overview
Journal Adipocyte
Date 2021 Oct 4
PMID 34602013
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Graves' orbitopathy (GO) is a serious, progressive eye condition seen in patients with autoimmune thyroid disease. GO is characterized by inflammation and swelling of soft orbital tissues. Adipose tissue produces cytokine mediators called adipokines. The present study focuses on the relationship between serum levels of selected adipokines in patients with GO, comparing them with the control group, and uniquely describes the effect of high-dose systemic corticosteroids (HDSC) on their levels. For the purposes of this study, we collected blood samples before and after the treatment with HDSC from 60 GO patients and 34 control subjects and measured serum levels of adiponectin, AIF-1, A-FABP and FGF-21. Levels of adiponectin significantly differed among the three study groups (ANOVA p = 0.03). AIF-1 levels were also significantly different among the study groups (ANOVA p < 0.0001). AIF-1 was significantly associated with the presence of GO after adjusting for clinical factors (age, sex, smoking and BMI) and level of TSH (odds ratio 1.003, p < 0.01). This finding could enforce targeting macrophages in treatment strategies for GO since AIF-1 is considered as a marker of their activation.

Citing Articles

Identification of optimal feature genes in patients with thyroid associated ophthalmopathy and their relationship with immune infiltration: a bioinformatics analysis.

Xiong C, Wang Y, Li Y, Yu J, Wu S, Wu L Front Endocrinol (Lausanne). 2023; 14:1203120.

PMID: 37900130 PMC: 10611488. DOI: 10.3389/fendo.2023.1203120.


The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.

Byeon H, Chae M, Ko J, Lee E, Kikkawa D, Jang S Invest Ophthalmol Vis Sci. 2023; 64(11):13.

PMID: 37555734 PMC: 10424154. DOI: 10.1167/iovs.64.11.13.


Novel inflammatory biomarkers in thyroid eye disease.

Ueland H, Ueland G, Lovas K, Breivk L, Thrane A, Meling Stokland A Eur J Endocrinol. 2022; 187(2):293-300.

PMID: 35675127 PMC: 9723260. DOI: 10.1530/EJE-22-0247.


Interplay between Fatty Acid Binding Protein 4, Fetuin-A, Retinol Binding Protein 4 and Thyroid Function in Metabolic Dysregulation.

Dadej D, Szczepanek-Parulska E, Ruchala M Metabolites. 2022; 12(4).

PMID: 35448487 PMC: 9026429. DOI: 10.3390/metabo12040300.

References
1.
Ozkaya M, Sahin M, Cakal E, Yuzbasioglu F, Sezer K, Kilinc M . Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest. 2009; 32(5):435-9. DOI: 10.1007/BF03346482. View

2.
Iglesias P, Diez J . Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine. 2007; 40(2):61-70. DOI: 10.1016/j.cyto.2007.10.001. View

3.
Zhao Y, Yan D, Chen Z . Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013; 284(1-2):75-83. DOI: 10.1016/j.cellimm.2013.07.008. View

4.
Oh S, Tung J, Priel A, Levi L, Granet D, Korn B . Reduction of orbital inflammation following decompression for thyroid-related orbitopathy. Biomed Res Int. 2013; 2013:794984. PMC: 3703426. DOI: 10.1155/2013/794984. View

5.
Smith T, Koumas L, Gagnon A, Bell A, Sempowski G, Phipps R . Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002; 87(1):385-92. DOI: 10.1210/jcem.87.1.8164. View